Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediciNova, Inc. - Common Stock (NQ:MNOV)

1.810 +0.180 (+11.03%)
Delayed Quote Updated: 1:13 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MediciNova, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Participate in Two Investor Conferences in September
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova CEO Provides Shareholder Update
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Participate at the 38th Annual ROTH Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
2026 New Year’s Greetings from the CEO
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
Message from the CEO to MediciNova Shareholders
Strengthening MN-001’s Scientific Foundation and Clinical Outlook 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
~Patient Recruitment Closed~ 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Provides Shareholder Update on Key Developments
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients 
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
From MediciNova, Inc.
Via GlobeNewswire
News headline image
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
News headline image
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy 
From MediciNova, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.